Table 1 Epidemiological studies of whole cannabis for anxiety (part 1)
From: Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties
Study | Data source | Number of participants | Route of administration | Dosage | Percent of respondents using for anxiety |
|---|---|---|---|---|---|
Sexton et al. 2016 [50] | Recruited via social media and Cannabis dispensaries in Washington State | 1429 | Inhalation (84.1%), Concentrates also typically inhaled (6.4%), Oral (8%), Topical: (0.6%), Fresh juice (0.5%), Other (0.4%) | 47.6% reported using 1–4 times per day 14.9% reported using 5–10 times per day 12.2% reported using all day, every day. 25.3% reported using less than once a day Dose is N/A | 58.1% |
Lintzeris et al. 2018 [51] | Recruited via online media and at professional and consumer forums | 1748 | Most frequent route was inhalation (83.4%) Oral Topical, suppository, and vaporiser routes used by only 29.4% of respondents | N/A | 51% |
Turna et al. 2019 [56] | An online survey was disseminated to all authorized CMP users registered with Canadian medicinal cannabis supplier Tilray | 2032 | 47.6% reported vaporising as the preferred mode of delivery, 21.4% preferred oral ingestion (edibles, oils, etc.) 18.5% preferred joints | 35% used < 1 g/day 42% used 1–2 g/day 23% used ≥ 3 g/day. | 43.7% |
Kosiba et al. 2019 [52] | Data were extracted from 13 studies that included participants from over 30 countries | 6665 | N/A | N/A | 52% |